Prescriva Tirzepatide Review: Monthly Price and Longer Plans

Prescriva's dedicated tirzepatide page lists $339 per month, or $289 per month on a 24-week plan. The distinction between those two terms is more important than simply choosing the lower monthly figure: the longer plan's complete payment and shipment obligations still need confirmation.¹

The platform identifies independent clinical care through OpenLoop and publishes both general terms and a separate refund policy. Those policies contain different descriptions of medical-disqualification refunds, so the selected plan's written terms matter.²³ This review uses current public information, without a purchase or clinical encounter.

A defined tirzepatide program

The product page describes compounded tirzepatide injections, clinician consultation, dose adjustments and shipping. It distinguishes research on approved tirzepatide from its compounded medication, rather than establishing that the compound itself has completed equivalent clinical trials.¹

The care description can help a patient compare what is being purchased. Ask whether the quoted plan includes every required clinical visit, how adjustments are handled between shipments and who answers clinical questions. A product's displayed dose schedule should not replace the patient's prescription.

Monthly and 24-week economics

The current tirzepatide page pairs the $339 monthly amount with the $289 monthly equivalent for the 24-week plan. These figures should not be confused with the separate semaglutide product's 48-week offer or with broad category comparison tables.¹

Request the total amount due, whether it is paid upfront or in installments, the supplied milligrams and the number of deliveries. If a longer plan changes after clinical review, find out how unused medication or uncompleted service is handled. A lower monthly equivalent does not establish the ability to leave after one month without further obligations.

The terms allow recurring services with the schedule specified at purchase and describe advance notice of price increases for subscriptions.² Save the actual quote, the next charge and the version of the terms you accept. That gives a firmer basis for comparison than assuming every promotional amount is interchangeable.

Clinical and dispensing roles

Prescriva's terms describe the business as a management services organization providing technology, marketing and administration. They identify OpenLoop Health and affiliated professional corporations as the independent clinical network.²

The platform does not make the prescription decision. Confirm the treating practice and clinician, the required encounter type in your state and the follow-up channel. If you need a live discussion before payment or a dose change, ask how that is arranged rather than assuming it follows automatically from submitting a quiz.

The terms describe state-licensed compounding pharmacies but do not establish your assigned dispenser.² Obtain that pharmacy's identity, contact details and state authorization. Ask for the formulation, concentration, storage requirements and the administration instructions accompanying your prescription.

State access and eligibility

The terms require adulthood, U.S. residence and a state where the provider network is licensed. They say availability varies with telehealth, prescribing and pharmacy rules.² The free-assessment invitation does not guarantee a prescription or the availability of the precise product in your location.

Confirm the actual service before providing payment authorization. A clinically unsuitable person should not interpret advertised inclusion of medication as a promise that any chosen drug will be prescribed. Your prescriber should discuss appropriate alternatives and the basis for a compounded rather than approved product.

Refund wording needs plan-specific clarity

The general terms say a patient found unsuitable after assessment is entitled to a consultation-fee refund. The separate refund policy describes medical-disqualification refunds for the current or most recent billing cycle, excludes prior cycles, and separately addresses out-of-stock medication and undelivered service.²³

Those descriptions should not be merged into an invented unconditional refund guarantee. Ask what is refundable if treatment is declined initially, becomes unsuitable later or cannot be fulfilled. Obtain the answer for the actual plan and billing period.

The policy says compounded medication already shipped is non-refundable, completed consultations are generally non-refundable and partial-cycle cancellation does not produce a prorated refund. It describes replacement handling for damaged or incorrect medicine.³ Distinguish those events from canceling future renewals, which the terms describe as ending at the current billing period's conclusion.²

Evidence and practical comparison

FDA explains that compounded GLP-1 medicines are not FDA-approved and do not undergo its premarket review. It recommends compounding only when a patient's needs cannot be met by an approved drug.⁴ The name tirzepatide does not independently verify the performance of a particular pharmacy preparation.

Prescriva provides a specific product and useful clinical/contract disclosures. Its strongest remaining purchasing questions are the total longer-plan commitment, individual dispensing assignment and applicable refund provision. No personal treatment outcome or independently certified facility quality is established here.

Compare the same dose and term with other providers, and include Zepbound cost options and the care-options guide in a clinician-led decision.

For other examples of longer-plan pricing and payment terms, see Ivologist and Näky.